Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.
Type:
Grant
Filed:
November 19, 2012
Date of Patent:
February 24, 2015
Assignee:
Cebix AB
Inventors:
John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels
Abstract: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including phosphodiesterase-5 (PDE5) inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to the PDE5 inhibitor alone.
Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
April 8, 2014
Assignee:
Cebix AB
Inventors:
Sheri Barrack, James Callaway, Michelle Mazzoni
Abstract: Improved methods and kits for treating the long-term complications of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits can also maintain good glycemic control and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
Type:
Application
Filed:
March 1, 2013
Publication date:
December 26, 2013
Applicant:
Cebix AB
Inventors:
John Wahren, Karin Ekberg, James Callaway
Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.
Abstract: The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
Type:
Application
Filed:
March 4, 2010
Publication date:
April 28, 2011
Applicant:
CEBIX AB
Inventors:
John Wahren, Karin Ekberg, James Callaway